RPg Family Wealth Advisory LLC Buys 165 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RPg Family Wealth Advisory LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,991 shares of the biopharmaceutical company’s stock after acquiring an additional 165 shares during the period. Regeneron Pharmaceuticals makes up about 1.8% of RPg Family Wealth Advisory LLC’s portfolio, making the stock its 22nd biggest holding. RPg Family Wealth Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $6,298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of the stock. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Finally, Family Firm Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $753.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The stock’s 50 day moving average is $929.13 and its 200-day moving average is $1,024.43. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $82.75 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.89 and a beta of 0.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.